Biosyent (TSXV:RX) Total Equity : C$35.00 Mil (As of Dec. 2024)

View and export this data going back to 1979. Start your Free Trial

What is Biosyent Total Equity?

Biosyent's total equity for the quarter that ended in Dec. 2024 was C$35.00 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Biosyent Total Equity Historical Data

The historical data trend for Biosyent's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biosyent Total Equity Chart

Biosyent Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Equity

Get a 7-Day Free Trial

26.80

31.56

33.36

34.76

35.00

Biosyent Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Equity	Get a 7-Day Free Trial															34.76	34.55	35.42	37.35	35.00

Biosyent Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Biosyent's Total Equity for the fiscal year that ended in Dec. 2024 is calculated as

Total Equity	=	Total Assets(Q: Dec. 2024 )	-	Total Liabilities(Q: Dec. 2024 )
	=	41.359	-	6.356
	=	35.00

Biosyent's Total Equity for the quarter that ended in Dec. 2024 is calculated as

Total Equity	=	Total Assets(Q: Dec. 2024 )	-	Total Liabilities(Q: Dec. 2024 )
	=	41.359	-	6.356
	=	35.00

Biosyent Total Equity Related Terms

Thank you for viewing the detailed overview of Biosyent's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Biosyent Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biosyent Inc (TSXV:RX) » Definitions » Total Equity

Comparable Companies

Traded in Other Exchanges

BIOYF:USA

Address

2476 Argentia Road, Suite 402, Toronto, Mississauga, ON, CAN, L5N 6M1

Website

http://www.biosyent.com

Biosyent Inc is a Canada-based growth-oriented specialty pharmaceutical company. It has focused on in-licensing or acquiring originative pharmaceuticals and other healthcare products. Its product includes FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Repagyn, and Tibella.m.

Executives

Peter Douglas Lockhard	Director
Blair Driscoll	10% Security Holder
Merrilyn Joy Driscoll	10% Security Holder
Sean Driscoll	10% Security Holder
Fax Capital Corp.	10% Security Holder
Fax Investments Inc.	10% Security Holder
Federated Capital Corp.	10% Security Holder
Seyed Ahmad Ashrafi	Director
Robert Joseph March	Senior Officer
Sharan Raghubir	Senior Officer
Rene Goehrum	10% Security Holder, Director, Senior Officer
Biosyent Inc.	Issuer
Joost Van Der Mark	Senior Officer
Sara Elford	Director
Alfred D'souza	Director

Biosyent Headlines

No Headlines